What is he best known for?
The fields of study he is best known for:
- Surgery
- Internal medicine
- Cancer
Surgery, Cartilage, Radiation therapy, Pathology and Orthopedic surgery are his primary areas of study.
Surgery is often connected to Sarcoma in his work.
His Chondrocyte study, which is part of a larger body of work in Cartilage, is frequently linked to Articular cartilage, bridging the gap between disciplines.
The Radiation therapy study which covers Disease that intersects with Fibromatosis.
In the field of Orthopedic surgery, his study on Chirurgie orthopedique overlaps with subjects such as Fracture fixation.
His Amputation research integrates issues from Osteosarcoma and Resection.
His most cited work include:
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee (5001 citations)
- Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. (1941 citations)
- The response of articular cartilage to mechanical injury. (1054 citations)
What are the main themes of his work throughout his whole career to date?
Henry J. Mankin mainly focuses on Surgery, Pathology, Cartilage, Osteosarcoma and Cancer research.
His study in Sarcoma extends to Surgery with its themes.
His work on Proteoglycan is typically connected to Articular cartilage as part of general Cartilage study, connecting several disciplines of science.
The various areas that Henry J. Mankin examines in his Osteosarcoma study include Metastasis and Chemotherapy.
His Cancer research research includes themes of Cell culture, Multiple drug resistance, Cancer, Cell growth and Apoptosis.
His research integrates issues of Lesion and Biopsy in his study of Soft tissue.
He most often published in these fields:
- Surgery (36.04%)
- Pathology (18.02%)
- Cartilage (15.26%)
What were the highlights of his more recent work (between 2004-2018)?
- Cancer research (10.55%)
- Surgery (36.04%)
- Osteosarcoma (11.53%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Surgery, Osteosarcoma, Cell culture and Cell growth.
His study in Cancer research is interdisciplinary in nature, drawing from both Cancer, Tissue microarray, Multiple drug resistance, Apoptosis and Molecular biology.
His Sarcoma research extends to the thematically linked field of Surgery.
The study incorporates disciplines such as Gene expression, Metastasis and Immunology in addition to Osteosarcoma.
His Cell culture study deals with Chordoma intersecting with Sacrum and MTT assay.
His study looks at the relationship between Cell growth and topics such as Kinase, which overlap with PLK1.
Between 2004 and 2018, his most popular works were:
- Articular cartilage and osteoarthritis. (650 citations)
- Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. (405 citations)
- Aneurysmal Bone Cyst: A Review of 150 Patients (270 citations)
In his most recent research, the most cited papers focused on:
- Surgery
- Internal medicine
- Cancer
Henry J. Mankin focuses on Cancer research, Surgery, Osteosarcoma, Cell growth and Cell culture.
The Cancer research study combines topics in areas such as Immunohistochemistry, Cancer, Tissue microarray, Apoptosis and Chordoma.
His Surgery study frequently draws connections between adjacent fields such as Radiology.
His Osteosarcoma research is multidisciplinary, incorporating elements of Small hairpin RNA, Gene knockdown, Doxorubicin, Sarcoma and Pharmacology.
As part of one scientific family, Henry J. Mankin deals mainly with the area of Cell growth, narrowing it down to issues related to the Molecular biology, and often microRNA and Receptor.
Henry J. Mankin studied Cell culture and PI3K/AKT/mTOR pathway that intersect with Cell, Cancer cell, Enzyme and Protein kinase B.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
